ESMO Clinical Practice Guidelines & MCBS
The ESMO guidelines are Europe's treatment algorithms, and the ESMO-MCBS scores how much each new drug actually helps.
ESMO-MCBS grades trials A-C (curative) and 1-5 (non-curative) on magnitude of benefit.
Pages like this
not linked directly; found by shared links- CollectionNCCN Guidelines
Shares A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer, Alert guidelines and trials when a paper they rely on is retracted, Guidelines list the open trials at every decision point, updated monthly, Label every biomarker claim with an evidence phase, like drugs.
- InstitutionNational Comprehensive Cancer Network (NCCN)
Shares Living guidelines published as versioned, computable rules, Fragmented care and guideline gaps, Knowledge reaches practice too slowly, Prices and value.
- InstitutionAmerican Society of Clinical Oncology (ASCO)
Shares A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer, ASCO clinical practice guidelines, Living guidelines published as versioned, computable rules, Weak real-world evidence and registries.
- IdeaReal-time guideline-concordance feedback for every cancer centre
Shares Living guidelines published as versioned, computable rules, Fragmented care and guideline gaps, Knowledge reaches practice too slowly.
- IdeaAudit whether tumour board recommendations were actually carried out
Shares Live guideline-concordance dashboards for every tumour board, generated from the record, Fragmented care and guideline gaps.
- IdeaBundled episode payments for cancer care with bonuses for guideline concordance
Shares Fragmented care and guideline gaps, Incentives reward me-too drugs and marginal gains, Prices and value.
- IdeaCap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales
Shares European Society for Medical Oncology (ESMO), Incentives reward me-too drugs and marginal gains, Prices and value.
- IdeaLiving, machine-readable guidelines pushed to the point of care in every country
Shares European Society for Medical Oncology (ESMO), Fragmented care and guideline gaps, Knowledge reaches practice too slowly.